| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Synairgen plc (PINK: SYGGF)
SYGGF Technical Analysis
1
| As on 4th Dec 2025 SYGGF STOCK Price closed @ 0.00 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SYGGFSTOCK Price
| Open | 0.00 | Change | Price | % |
| High | 0.00 | 1 Day | N/A | N/A |
| Low | 0.00 | 1 Week | 0.00 | 0.00 |
| Close | 0.00 | 1 Month | 0.00 | 0.00 |
| Volume | 2000 | 1 Year | 0.00 | 0.00 |
| 52 Week High 0.00 | 52 Week Low 0.00 | ||||
PINK USA Most Active Stocks
| CBGL | 0.00 | % |
| TXGE | 3316.21 | 2.69% |
| VIVK | 0.07 | 0.00% |
| BFCH | 0.00 | % |
| UMAV | 0.00 | % |
| TMSH | 0.00 | % |
| APLD | 27.86 | -9.43% |
| XTRM | 0.00 | % |
| WHEN | 0.00 | % |
| CRWG | 3.73 | -20.30% |
PINK USA Top Gainers Stocks
PINK USA Top Losers Stocks
| SYGGF Daily Charts |
SYGGF Intraday Charts |
Whats New @ Bazaartrend |
SYGGF Free Analysis |
|
|
SYGGF Important Levels Intraday
| RESISTANCE | 0.00 |
| RESISTANCE | 0.00 |
| RESISTANCE | 0.00 |
| RESISTANCE | 0.00 |
| RESISTANCE | 0.00 |
| RESISTANCE | 0.00 |
| RESISTANCE | 0.00 |
| RESISTANCE | 0.00 |
SYGGF Forecast December 2025
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
SYGGF Weekly Forecast
| 4th UP Forecast | 0.00 |
| 3rd UP Forecast | 0.00 |
| 2nd UP Forecast | 0.00 |
| 1st UP Forecast | 0.00 |
| 1st DOWN Forecast | 0.00 |
| 2nd DOWN Forecast | 0.00 |
| 3rd DOWN Forecast | 0.00 |
| 4th DOWN Forecast | 0.00 |
SYGGF Forecast2025
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
Synairgen plc ( PINK USA Symbol : SYGGF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SYGGF Business Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Address: Mailpoint 810, Southampton, United Kingdom, SO16 6YD
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service